Sevelamer Fast Dissolving Tablet with Hydrophobic Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral phosphate binders, particularly sevelamer, face challenges such as high hydroscopicity, bitter taste, and swelling in the oral cavity, leading to manufacturing difficulties and reduced patient compliance due to discomfort and inconvenience.
Innovation Solution
A fast dissolving composition of sevelamer or its pharmaceutically acceptable salts, combined with excipients that form hydrogen bonds or provide a coating to minimize swelling, ensuring rapid disintegration, pleasant taste, and high phosphate binding capacity with minimal water intake, is developed. This composition includes binders like povidone and waxes, along with diluents and flavoring agents to enhance mouth feel and pharmacotechnical properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sevelamer is used as a phosphate binder, then high phosphate binding capacity is achieved, but swelling in the oral cavity occurs causing patient discomfort
Solution Approach 1:
The patent introduces an intermediary substance (hydrophobic coating or wax matrix) that mediates between the hydrophilic sevelamer polymer and the oral environment. This coating acts as a barrier that prevents excessive water absorption and swelling while allowing the phosphate binding function to occur. The intermediary layer controls the interaction between sevelamer and oral fluids, resolving the contradiction between maintaining binding capacity and preventing harmful swelling.
Solution Approach 2:
The patent applies a hydrophobic coating or wax matrix as a protective shell around the sevelamer-containing formulation. This thin film or shell structure limits water penetration to controlled levels, preventing the uncontrolled swelling that occurs with plain sevelamer. The flexible barrier maintains the integrity of the formulation in the oral cavity while allowing sufficient phosphate binding activity.
2Reliability
If sevelamer is used as a phosphate binder, then high phosphate binding capacity is achieved, but bitter taste and unpleasant mouth feel occur reducing patient compliance
Solution Approach 1:
The hydrophobic coating or wax matrix serves as a sensory intermediary that masks the bitter taste and unpleasant mouth feel of sevelamer. This coating layer acts as a barrier between the patient's taste buds and the bitter polymer, allowing the therapeutic function to proceed while improving sensory acceptance. The intermediary protects the patient from the harmful sensory effects while preserving the beneficial phosphate binding action.
Solution Approach 2:
The patent uses a hydrophobic coating or wax film to encapsulate the sevelamer particles, creating a protective shell that prevents direct contact between the bitter polymer and oral tissues. This thin film barrier masks the unpleasant taste and texture while allowing the formulation to dissolve and release sevelamer for phosphate binding. The shell structure resolves the contradiction between maintaining therapeutic efficacy and improving sensory acceptability.
3Reliability
If conventional phosphate binders are used, then phosphate binding is achieved, but large tablet size makes them difficult to swallow particularly for elderly and children
Solution Approach 1:
The patent employs a wax matrix or hydrophobic coating that enables compression of sevelamer into smaller, more manageable tablet forms. The flexible nature of the wax or coating allows the formulation to be compressed into compact sizes that are easier to swallow, while still maintaining the phosphate binding function. This shell or matrix structure enables miniaturization of the dosage form without sacrificing therapeutic activity.
Solution Approach 2:
The patent creates a composite material system combining sevelamer with hydrophobic waxes or coating agents. This composite formulation integrates the phosphate binding polymer with hydrophobic excipients that enable smaller tablet size and improved swallowability. The composite structure resolves the contradiction between maintaining binding function and reducing volume for easier administration to elderly and pediatric patients.
4Reliability
If sevelamer is used as a phosphate binder, then effective phosphate binding is achieved, but high hydroscopicity causes manufacturing difficulties
Solution Approach 1:
The hydrophobic coating or wax matrix acts as a manufacturing intermediary that protects the hydrophilic sevelamer polymer from excessive moisture absorption during processing. This coating layer serves as a barrier that prevents uncontrolled hygroscopy, making the formulation easier to handle, weigh, and compress during manufacturing. The intermediary enables standard pharmaceutical manufacturing processes to be applied to this hydrophilic polymer without the difficulties associated with high moisture sensitivity.
Solution Approach 2:
The patent applies a hydrophobic coating or wax shell around the sevelamer-containing formulation to protect it from moisture during manufacturing operations. This thin film barrier prevents the polymer from absorbing excess atmospheric moisture, which would otherwise cause handling difficulties, weight variations, and compression problems. The protective shell enables easier manufacturing while preserving the phosphate binding effectiveness of the sevelamer.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution results in a formulation that is easy to manufacture, non-swelling, and provides effective phosphate binding with fast kinetics, improving patient compliance and ease of administration while maintaining the high phosphate binding capacity of sevelamer.
Implementation Method 1
These amines become partially protonated in the intestine and interact with phosphate and other ions through ionic and hydrogen bonding
Implementation Method 2
These amines become partially protonated in the intestine and interact with phosphate and other ions through ionic and hydrogen bonding
Implementation Method 3
combined with excipients that form hydrogen bonds or provide a coating to minimize swelling
Data Source
Figure 1
Figure 2(A)~2(B)
AI summary
The present invention relates to a fast dissolving tablet comprising a therapeutically effective amount of a phosphate binding polymer, such as sevelamer or pharmaceutically acceptable salt or derivative thereof, that exhibit limited swelling in the oral cavity, has pleasant taste and mouth feel, high phosphate binding capacity with fast binding kinetics and require limited amount of water intake.. A process for the preparation thereof is disclosed.